Research And Development Of Full-automatic Fluorescence In Situ Hybridization System Device

Fluorescence in situ hybridization,a combination of non-radioactive molecular biology and cytogenetics,was gradually developed in the late 1980 s on the basis of radioactive in situ hybridization.Because of its advantages of safe use,short experimental period,high accuracy and convenient observation,it is popular in the diagnosis of prenatal,tumor and blood diseases.However,because the process of the technology is complicated and cumbersome,the reagent consumables required are extremely expensive,and the technology is still mainly in the manual operation stage,relying on the professional quality of the operator,and the cost of technical training is very expensive,which greatly reduces the utility of the technology and greatly restricts the use and popularization of the technology.Some of the world's best-known medicaldevice companies,such as Leica in Germany,and Philips in Netherlands,have developed automation devices,but their solutions have been largely done with multiple combinations of devices,and the key steps still require manual operation.The time of operation and the consumption of reagents are not much superior to manual operation.In view of the development of fluorescence in situ hybridization technology and its automation,this paper studies and develops the automatic fluorescence in situ hybridization system with high automation degree,low reagent consumption and high treatment efficiency.In order to solve the complex and key problems in the process of molecular diagnosis of liquid-based cells,this paper studies the automatic liquid-based cell fluorescence in situ hybridization system based on microfluidic chip technology with low reagent consumption,fast detection speed,simple operation,multi-function integration and small reaction volume.A large-throughput fully automatic fluorescence in situ hybridization system for large hospitals and inspection institutions and a digital micro-valve-based POCT(immediate inspection,Point of Care Testing)fluorescence in situ hybridization system for small and medium-sized community hospitals were designed for different usage requirements.Compared with the existing equipment,the device developed in this paper has the following advantages:(1)the complete flow automation of the fluorescence in situ hybridization technology can be accomplished for the first time with only one installation;(2)the reaction cavity of the closed microfluidic chip can save 80% reagent consumption under the premise of ensuring the experimental effect of the fluorescence in situ hybridization,while the unique multi-reaction cavity chip can greatly increase the sample size per unit area,which can reduce the volume of the equipment and ensure the sample processing capacity;(3)the 24 h processing time required by the traditional method can be reduced to 4 hours,and the processing efficiency can be improved significantly;(4)the micro-cavity of the integrated microfluidic chip technology and the simple automatic control technology can replace the traditional complex control,high-cost and large-volume liquid delivery,which can reduce the complex degree of cost and the complex degree of the control capacity of the reagent.The key technical indexes of the device developed in this paper have reached the international advanced level,and its successful development can greatly expand the application market of fluorescent in situ hybridization technology,Promote the development of China's medical treatment to precision medicine and individualized medicine,and quickly build a fully automated,miniaturized and intelligent medical inspection product for the diagnosis of liquidbased cell molecules.